Search Results
Your search for all items matches 34830 pages
Showing 601 - 650Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Filho et al, 12-year follow-up of the CALBG (Alliance) C9741 trial has shown a sustained advantage of adjuvant dose-dense vs conventional chemotherapy in disease-free and overall survival in patients with node-positive breast cancer. Study Details...
Mobility Patterns and Survival Disparities in Patients With Cancer
A recent study published in Health Data Science, conducted by Fengyu Wen, PhD, MPH, of the Institute of Medical Technology at Peking University Health Science Center; Luxia Zhang, MD, MPH, of the National Institute of Health Data Science at Peking University; and colleagues, revealed significant...
Improvements in BRCA2 Testing Could Enhance Cancer Risk Assessment, Patient Care
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study published by Huang et al in Nature. The findings could improve the accuracy of genetic testing and allow health-care professionals to offer more precise risk assessments and...
New Study Identifies Genes That Could Be Implicated in Glioblastoma in Adulthood
Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...
Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study
A team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with melanoma will respond to immunotherapy. Their findings, published in JCO Oncology Advances, may help clinicians to...
Use of Denileukin Diftitox-cxdl in Relapsed or Refractory CTCL
In a registrational trial reported in the Journal of Clinical Oncology, Foss et al found that denileukin diftitox (DD)-cxdl—a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2—was active in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)....
Belzutifan Plus Cabozantinib as First-Line Treatment in Advanced Clear Cell Renal Cell Carcinoma
In a phase II trial (LITESPARK-003), reported in The Lancet Oncology, Choueiri et al found that the combination of belzutifan—a first-in-class HIF-2α inhibitor—and cabozantinib showed promising activity in the first-line treatment of patients with advanced clear cell renal cell carcinoma. Study...
OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer
For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with placebo, according to the third interim analysis of the phase III OlympiA trial presented at the 2024...
Belinda Avalos, MD, Begins Term as 2025 ASH President
Belinda Avalos, MD, Professor of Medicine and a senior advisor to the President of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2025. Overview Dr. Avalos is a physician-scientist with a special clinical...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study published by Mabena et al in British Journal of Sports Medicine. The findings revealed that even relatively low levels of physical activity may be...
Study Identifies Potential New Target to Overcome Breast Cancer Resistance
A new University of Cincinnati (UC) Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes. The research was recently published in the journal Cancers. Study Background Study author...
Final Overall Survival Results From SOLO3 Trial: Olaparib vs Nonplatinum Chemotherapy in Platinum-Sensitive BRCA-Mutated Relapsed Ovarian Cancer
As reported in the Journal of Clinical Oncology by Scambia et al, the final overall survival results of the phase III SOLO3 trial showed similar outcomes with olaparib vs non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In the initial report...
Nivolumab Plus AVD as Front-Line Therapy in Older Adults With Classical Hodgkin Lymphoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Torka et al found that the addition of nivolumab to standard doxorubicin, vinblastine, and dacarbazine (N-AVD) was “highly effective” as front-line treatment for patients aged ≥ 60 with classical Hodgkin lymphoma. Study Details In...
Addition of Palbociclib to Standard Therapy in Metastatic Hormone Receptor–Positive, HER2-Positive Breast Cancer
Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with hormone receptor (HR)-positive,...
Oncology Society Urges Americans to Heed Surgeon General’s Advisory on Alcohol and Cancer
On January 3, 2025, the U.S. Surgeon General’s office released a new advisory on the link between alcohol consumption and increased risk for cancer. The advisory reports alcohol use as the third leading preventable cause of cancer in the United States—after tobacco and obesity—responsible for...
Effect on Ki67 Index of High Omega-3, Low Omega-6 Diet With Fish Oil in Prostate Cancer During Active Surveillance
In a single-institution phase II trial (CAPFISH-3) reported in the Journal of Clinical Oncology, Aronson et al found that men with prostate cancer on active surveillance had a significantly reduced Ki67 index on a high omega-3, low omega-6 fatty acid diet with fish oil capsules vs no dietary...
Risk-Adapted Active Surveillance After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
In a phase II trial (RETAIN 1) reported in the Journal of Clinical Oncology, Geynisman et al found that risk-adapted active surveillance following neoadjuvant chemotherapy was associated with a high rate of metastasis-free survival in patients with muscle-invasive bladder cancer. Study Details In ...
Role of Cancer Gene in Esophageal Adenocarcinoma May Support Paradigm Shift in Predicting Disease
A genetic mutation long believed to drive the development of esophageal cancer may play a protective role early in the disease, according to a recent study published by Ganguli et al in Nature Cancer. The findings could help physicians identify which patients are at greater risk of developing...
Glucarpidase May Improve Recovery Following Methotrexate-Induced Kidney Toxicity
The drug glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy agent methotrexate, according to a recent study published by Gupta et al in Blood. Background As a result of its ability to penetrate the blood-brain barrier, methotrexate is one of the most...
Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial
Presented by Sherko Kuemmel, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium The WSG ADAPT trial in patients with HR-positive, HER2-negative breast cancer established that the combination of clinical risk, genomic risk, and endocrine response (Ki67 downregulation) allows...
Komal Jhaveri, MD, FACP on The Phase III EMBER Trial
At the San Antonio Breast Cancer Symposium, Komal Jhaveri, MD, FACP, presented results of the phase III EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader as monotherapy and combined with abemaciclib for patients with ER+/HER2-negative advanced breast cancer. Filmed...
Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds
Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing surgeries, including bilateral mastectomy and/or salpingo-oophorectomy, according to data...
HRQOL With Endocrine Therapy vs Radiotherapy After Breast-Conserving Surgery in Older Women With Luminal A–Like Early Breast Cancer
As reported in The Lancet Oncology by Meattini et al, interim analysis of the phase III EUROPA trial indicated that endocrine therapy was associated with poorer health-related quality of life (HRQOL) outcomes vs radiotherapy after breast-conserving surgery in women aged ≥ 70 years with luminal...
RELATIVITY-047: Extended Analysis of Overall Survival With Nivolumab/Relatlimab vs Nivolumab in Previously Untreated Advanced Melanoma
In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma. The initial...
Psilocybin-Based Therapy May Address Mental Health Issues in Patients With Cancer, Addiction
Treatment with psilocybin may improve mental health issues among patients with cancer when accompanied by psychotherapy and could result in lasting, positive personality changes in patients with alcohol use disorder, according to two recent studies published by Petridis et al in Nature Mental...
Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
Researchers have found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought, according to a recent study published by Holzgreve et al in JAMA Network Open. Background Prostate-specific membrane antigen–positron-emission tomography ...
Jame Abraham, MD, FACP on the PATINA Trial
Presented by Otto Metzger, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The phase III PATINA trial showed that the addition of palbociclib to current standard-of-care first-line maintenance therapy, following induction...
Jame Abraham, MD, FACP on the Phase III ZEST Trial
Presented by Nicholas Turner, MD, PhD, on December 13, 2024 at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The ZEST phase III clinical trial was designed to evaluate the potential of the PARP inhibitor niraparib to prevent breast cancer recurrence in...
Trends in Early-Onset Colorectal Cancer
As reported in The Lancet Oncology by Sung et al, analysis of international population-based cancer registry data indicate an increase in incidence of colorectal cancer among younger persons (age < 50 years) in a majority of countries and territories examined. Study Details Colorectal cancer...
Surgeon General’s Report Calls for Cancer Warning Labels on Alcoholic Beverages
Today, Surgeon General Dr. Vivek Murthy issued an advisory citing scientific studies linking alcoholic beverages and an increased risk of at least seven cancers, including breast and colorectal cancers, and called for alcoholic beverages to carry cancer warning labels. Health warning labels on...
New Research Approaches to Metastatic Breast Cancer
Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded...
Novel Combination Regimen May Prevent Squamous Cell Carcinoma
A recent study by Demehri et al of Mass General Brigham investigates whether calcipotriol—a vitamin D analog—plus fluorouracil may prevent squamous cell carcinoma (SCC), with benefits lasting 5 years after treatment. This combination therapy is the first to activate specific components of the...
Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancers
As reported in the Journal of Clinical Oncology by Shroff et al, the phase III SWOG S1815 trial showed that nab-paclitaxel plus gemcitabine/cisplatin (GAP regimen) did not significantly improve overall survival vs gemcitabine/cisplatin alone in newly diagnosed patients with advanced biliary tract...
Novel Prognostic Tool in Hormone Receptor–Positive, HER2-Negative, Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology, Pusztai et al developed the RSClinN+ tool—an integration of the 21-gene Oncotype DX Breast Recurrence Score (RS) test and clinicopathologic factors (tumor grade, tumor size, age)—that improved prognosis for invasive disease–free survival vs RS alone...
Maintenance Therapy After Induction With RVd With or Without Isatuximab in Transplant-Eligible Newly Diagnosed Multiple Myeloma
As reported in the Journal of Clinical Oncology by Mai et al, the German phase III GMMG-HD7 trial (Part 1) showed that the addition of isatuximab (Isa) to standard-of-care lenalidomide/bortezomib/dexamethasone (RVd) improved progression-free survival irrespective of maintenance therapy strategy in...
Studies Point to the Role of Diet in Hematologic Malignancies
According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...
NPM1 Genotypes and Outcomes in AML
In an AIEOP-BFM and COG-SWOG intergroup collaborative study reported in the Journal of Clinical Oncology, Tregnago et al found that patients with acute myeloid leukemia (AML) with NPM1 type D variants had significantly poorer event-free and overall survival vs those with non-D variants. Study...
Nuclear Speckle Signatures in Clear Cell RCC
Researchers have found a possible source of the variability in patterns of clear cell renal cell carcinoma (RCC), the most common kidney cancer diagnosed in adults. Katherine Alexander, PhD, Assistant Professor at Cold Spring Harbor Laboratory, and Shelley Berger, PhD, Professor at the University...
AI May Improve Ovarian Cancer Diagnoses
A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is published in Nature Medicine. “Ovarian tumors are common and are often detected by chance,” said...
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer
On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected...
SEQUOIA 5-Year Follow-up: Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
As reported in the Journal of Clinical Oncology by Shadman et al, 5-year follow-up of the phase III SEQUOIA trial demonstrated that zanubrutinib continued to show a progression-free survival benefit over bendamustine plus rituximab in previously untreated patients with chronic lymphocytic...
CTX130 CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma
In a phase I dose-escalation study (COBALT-LYM) reported in The Lancet Oncology, Iyer et al found that CTX130 (volamcabtagene durzigedleucel)—a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured from healthy donor T cells—had a manageable safety profile and showed...
Long-Term Overall Survival With Adjuvant Gemcitabine/Capecitabine vs Gemcitabine in Pancreatic Adenocarcinoma
In a long-term analysis of the phase III ESPAC4 trial reported in Journal of Clinical Oncology, Palmer et al found adjuvant gemcitabine/capecitabine (Gem/Cap) was associated with prolonged overall survival vs gemcitabine monotherapy in patients with pancreatic adenocarcinoma. Study Details In...
Patient With Transfusion-Dependent Myelofibrosis and Severe Thrombocytopenia
This is Part 3 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a transfusion-dependent patient with...
Patient With Ruxolitinib-Treated Myelofibrosis Who Develops Anemia
This is Part 2 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a patient with myelofibrosis who develops...
Patient With Newly Diagnosed Myelofibrosis and Moderate Anemia
This is Part 1 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the first-line treatment of a newly diagnosed patient with...
Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an increased risk of leukemia compared with other first responders or members of the public who were not...
MRI-First Strategy May Be Safe for Prostate Cancer Detection
Researchers have examined whether a magnetic resonance imaging (MRI)-first approach is safe for prostate cancer detection over the long term, according to a recent study published by Hamm et al in JAMA Oncology. Background Several strategies may be deployed for the early detection of prostate...
